SLC27A3 and neoplasm: In the presence of pazopanib, an obvious decrease in tumor luciferase activity was observed in the SLC27A3 knockdown group (Fig. 2J and Fig. S2I), accompanied by a reduction in tumor size (Fig. 2K and Fig. S2I).